查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835327

流感诊断市场（按技术和最终用户划分）—2025-2032 年全球预测

Influenza Diagnostics Market by Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年流感诊断市场规模将成长至 28.6 亿美元，复合年增长率为 10.15%。

主要市场统计数据
基准年2024年 13.2亿美元
预计2025年 14.5亿美元
预测年份：2032年 28.6亿美元
复合年增长率（%） 10.15%

临床、技术和营运驱动因素的策略方向，将改变整个医疗保健环境中的流感诊断

流感诊断领域正在加速演变，这得益于日益增长的防范需求、日益成熟的技术以及临床工作流程的系统级转变。诊断需求正从季节性偶发性检测扩展到多重呼吸道检测、疫情高峰期的即时筛检以及对易感人群的治疗后监测。同时，实验室整合和检测分散化正在重塑诊断服务的提供和使用方式。

临床相关人员越来越重视速度、分析效能和操作简便性，而医疗保健系统则强调吞吐量、供应弹性和成本效益。这些相互交织的优先事项使得诊断产品开发人员和行销人员必须将产品设计与实际用例（包括医院实验室、门诊诊所、学术中心和高容量诊断实验室）相结合，这已成为一项战略要务。此外，监管透明度和报销途径仍然是推动产品采用的关键因素，因此必须主动将产品开发时间表与政策预期相协调。

在此背景下，本报告整合了临床驱动因素、技术准备、供应链考量和相关人员奖励，旨在为短期商业策略和长期投资决策提供参考。报告旨在为临床负责人、研发团队和商业负责人提供一个可行的框架，帮助他们应对复杂的临床需求、绩效权衡和营运限制。

技术创新、监管演变和营运弹性如何共同重新定义流感诊断的提供地点、方式和人员。

近年来，流感诊断领域发生了重大变化。分子检测方法的加速应用推动了对即时诊断 (POC) 解决方案的需求，改变了集中式和分散式检测模式之间的平衡。等温扩增和整合试剂盒平台的创新为传统 PCR 工作流程提供了强大的替代方案，在许多用例中实现了快速、更贴近患者的诊断，且不影响分析灵敏度。同时，多重检测技术的改进使得同时检测多种呼吸道病原体成为可能，从而扩展了临床效用。

这些技术进步与营运模式的转变相伴而生。卫生系统正在投资灵活的检测能力，以应对季节性激增和意外疫情；实验室则优先考虑工作流程自动化和数位化集成，以提高通量和数据连接性。供应链弹性已成为重中之重，负责人采取多样化的筹资策略，并尽可能寻求本地生产。此外，全球监管机构正在完善紧急使用和加速核准流程，为能够证明临床价值和营运适用性的创新诊断方法提供了机会。

这些转变并非仅仅是渐进式的；它们改变了检测的地点、检测的执行者以及检测结果对患者预后的影响。因此，策略参与者必须预见日益成熟的技术、不断发展的法规和买家预期的交汇，才能保持竞争力和临床相关性。

评估关税主导的贸易变化对诊断价值链中的供应链、筹资策略和采购偏好的多方面影响

征收关税和贸易措施可能会对整个诊断生态系统产生连锁反应，影响零件成本、供应链设计和商业策略。关税相关的成本压力可能会推高进口试剂、耗材和仪器零件的国内价格，促使製造商重新评估其全球筹资策略，迁移敏感的生产业务，并协商签订长期供应协议。为此，一些公司正在加快努力实现供应商多元化，并寻找既能保持性能又能降低贸易中断风险的替代材料。

除了直接的成本影响外，关税还会改变国产产品与进口产品的相对吸引力，进而影响竞争动态。对于在全球营运的诊断公司而言，关税可能会促使它们调整分销布局和定价策略，以在保持市场进入的同时保护净利率。面临采购限制的卫生系统和实验室可能会更加重视供应弹性和供应商风险管理，从而影响采购合约和首选供应商名单。

监管和采购环境也将随之调整。除了关税之外，政策制定者还可能实施奖励，以提升国内生产能力，加速国产诊断产品的监管审查，并采取策略性储备措施。因此，能够展示本地生产能力、强大供应链和合规性的公司将获得策略优势。最终，应对关税环境需要製定一个综合的跨职能计划，协调采购、製造、监管和商业团队，以保持产品供应并保障临床的连续性。

详细的細項分析揭示了技术模式和最终用户管道如何决定产品规格、采用趋势和商业性方法

流感诊断细分涵盖技术模式和最终用户管道，每种模式和管道都有不同的效能预期和营运限制。在技​​术路径内，分子诊断包括传统的聚合酵素链锁反应方法、等温扩增技术和即时PCR平台。传统 PCR 继续用于优先考虑通量和全面验证的参考实验室，而等温扩增方法（恒温环型核酸扩增和基于核酸序列的扩增）由于其简单性和适用于分散式检查而越来越受欢迎。即时PCR具有支援多重和单重的配置，仍然是高灵敏度应用和确认工作流程的核心。快速诊断包括基于墨盒的平台，该平台整合了用于近患者使用的样品处理和检测以及横向流动化验，可提供快速、低成本的筛检选项。血清学诊断包括酵素结合免疫吸附试验、血凝抑制试验和中和试验，这些对于免疫状态​​评估、疫苗评估和流行病学监测至关重要。

从最终用户的观点，学术和研究机构寻求支援方法开发和复杂面板的灵活平台，而诊所则寻求能够提供快速可操作结果的紧凑、易于使用的解决方案。诊断实验室优先考虑吞吐量、自动化和数据互通性，而医院则寻求与实验室资讯系统整合并支援住院护理途径的可扩展解决方案。技术选择和最终用户需求之间的相互作用推动了产品规格、商业性包装和支援模型。例如，多重即时PCR解决方案非常适合分析深度和吞吐量至关重要的标准实验室和大型医院，而等温和基于墨盒的系统更适合门诊诊所和分散式检查设施。认识到这种一致性使供应商能够调整打入市场策略，确定监管环境的优先级，并设计符合临床营运现实的服务产品。

区域医疗保健基础设施、法规环境和製造地如何影响不同的诊断采用模式和策略重点

流感诊断的区域动态反映了美洲、欧洲、中东和非洲以及亚太地区医疗保健基础设施、管理体制和供应链架构的差异。在美洲，成熟的实验室网路和强大的报销框架正在推动对高效能分子检测和整合实验室解决方案的需求。在欧洲、中东和非洲，协调监管环境和不同医疗保健系统能力的努力正在创造一种异质格局，其中集中式实验室与不断增加的分散式检查投资并存，以改善医疗服务的可及性，尤其是在偏远和资源匮乏的地区。在该地区，采购惯例和公共卫生监测重点正在影响产品的选择和分销模式。

在亚太地区，製造能力、政府主导的检测计划以及新平台的快速应用，使该地区成为诊断组件和检测试剂的主要消费地和关键生产中心。本地製造商正在扩大其分子和快速诊断製造能力，以增强该地区供应链的韧性，并支援针对大批量检测环境的客製化解决方案。这些地区差异影响着监管策略、经销伙伴以及临床检验工作的在地化。因此，寻求区域扩张的公司必须根据每个地区独特的期望和基础设施现状，调整其监管提交、本地支援模式和供应物流。

平台整合、策略伙伴关係和本地生产的竞争动态将决定差异化和长期采购关係

流感诊断领域的竞争格局以成熟的诊断製造商、专业的分子创新者以及不断扩张的试剂盒和即时诊断平台开发商网路为特征。产业领导者持续整合其平台，扩展其检测菜单，并投资于全球分销，利用其规模优势来支援服务模式、品质保证和法规申报。同时，敏捷的科技公司正在推动恆温方法、实验室晶片整合和增强型快速抗原检测能力等创新，并经常与临床实验室和研究机构合作，以检验新的应用。

设备供应商和检测开发商之间的策略伙伴关係正变得日益重要，这有助于快速将新型检测引入临床，并建立连接硬体、耗材和数位服务的生态系统。同时，契约製造和本地生产基地已成为供应保障策略的关键组成部分，尤其是在贸易措施和物流中断限制跨境流动的情况下。那些能够展现出强大的资料包品质、响应迅速的技术支援和灵活商业模式的公司，很可能在赢得与医疗系统和大型实验室网路的多年期采购合约方面占据有利地位。鑑于这些动态，产业相关人员必须在产品创新与临床客户所需的营运严谨性之间取得平衡。

相关人员可采取的优先事项包括加强供应弹性、使产品设计与临床工作流程保持一致以及透过策略伙伴关係加速采用

产业领导者可以采取积极主动的措施，增强韧性，加速产品采用，并获得临床价值。首先，将产品开发与优先的临床工作流程（例如，快速门诊排除或住院患者管理的多重检测组合）相结合，以确保产品性能特征转化为临床医生的实际利益。其次，投资于供应链多元化和区域製造能力，以减少贸易中断带来的风险，并在需求激增期间支援更快的交付时间。第三，与实验室网路、卫生系统和学术中心建立策略合作伙伴关係，以加速现实世界的检验，并与大型采购商建立信任。

此外，公司必须将监管策略作为竞争优势，协调证据产生以支持目标全部区域的核准途径，并预测监管预期的变化。商业性角度来看，弹性价格设定和服务模式能够反映付款方的限制和采购週期，从而实现更广泛的应用，尤其是在分散的环境中。最后，将数位连接和数据分析融入产品中，可以透过实现品管、远端故障排除以及与电子健康记录的整合来提升客户价值。透过执行这些必要措施，领导者可以将技术优势转化为持续的临床和商业性成果。

我们的证据主导方法结合了主要相关人员访谈、监管和技术文件审查以及跨源三角测量，以确保严谨且可操作的调查结果

本研究结合了临床实验室主任、采购人员和产品开发主管的初步访谈，以及对监管指南、同行评审文献以及仪器和检测试剂供应商的检验技术规范的二次研究。调查方法和资料来源经过三角检验，以确保研究的稳健性。定性洞察为技术采用叙述提供讯息，而技术文件则构成了性能表征和互通性考虑的基础。

在现场访问期间，我们进行了结构化对话，以了解医院、诊断实验室、诊所和学术中心的营运限制、采购标准和临床决策驱动因素。这些洞察与监管文件和产品技术手册进行了交叉比对，以确认声称的功能与实际营运的一致性。分析框架优先考虑技术准备、整合复杂性和供应链相关人员寻求在本地检验特定要素的利害关係人提供了可复製性。

总结性结论强调，技术创新、营运弹性和策略协调是诊断领域持久成功的先决条件

不断发展的流感诊断环境既充满复杂性，也蕴含着机会。分子检测和快速检测技术的进步，以及医疗保健的日益分散化和供应链审查的加强，正在重新定义临床客户的价值驱动力。同时，地缘政治和贸易发展凸显了灵活采购和区域製造策略的必要性。产业参与者的成功将取决于他们能否将技术创新与卓越营运相结合，满足不同司法管辖区的监管要求，并透过真实世界检验证明其切实的临床有效性。

清晰的策略根植于对终端使用者工作流程、区域基础设施和竞争定位的理解，使企业能够优先考虑能够带来差异化价值的投资。可靠的供应，加上以客户为中心的服务模式、监管准备以及有针对性的伙伴关係关係，使主导能够在稳定和快速增长的需求环境中保持领先地位。最终，基于严谨证据的明智行动以及与临床相关人员的密切合作，将决定谁能抓住流感诊断领域最持久的商机。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 快速分子就地检验的扩展将允许在几分钟内检测到患者附近的流感。
  • 开发整合甲型/乙型流感及其他病毒和细菌标靶的多重呼吸道检测组
  • 采用基于 CRISPR 的诊断检测方法对流感病毒株进行灵敏检测
  • 整合数位健康平台，用于远端监控和报告流感检测结果
  • 家用流感检测自采集套件的出现，并配有远端医疗医疗指导解读
  • 利用次世代定序进行全面的流感病毒监测和突变追踪
  • 传播基于生物标记的预后测试，针对重症流感患者的标靶治疗
  • 越来越多地使用人工智慧分析来预测流感爆发并优化诊断资源分配

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章流感诊断市场（按技术）

  • 分子诊断
    • 常规PCR
    • 等温扩增
      • 环介导等温扩增
      • 基于核酸序列的扩增
    • 即时PCR
      • 多重PCR套件
      • 单重PCR套件
  • 快速诊断
    • 基于墨盒的平台
    • 横向流动化验
  • 血清学诊断
    • 伊丽莎
    • 抑制红血球聚集
    • 中和试验

第九章 流感诊断市场（依最终用户）

  • 学术研究机构
  • 诊所
  • 诊断实验室
  • 医院

第 10 章流感诊断市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第11章流感诊断市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十二章 流感诊断市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十三章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Quidel Corporation
    • Becton, Dickinson and Company
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Hologic, Inc.
    • Luminex Corporation
    • Meridian Bioscience, Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market is projected to grow by USD 2.86 billion at a CAGR of 10.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.32 billion
Estimated Year [2025] USD 1.45 billion
Forecast Year [2032] USD 2.86 billion
CAGR (%) 10.15%

A strategic orientation to the changing clinical, technological, and operational drivers reshaping influenza diagnostics across healthcare delivery settings

The landscape of influenza diagnostics is undergoing a period of accelerated evolution driven by heightened preparedness demands, technological maturation, and system-level shifts in clinical workflows. Diagnostic needs have expanded beyond episodic seasonal testing to encompass multiplexed respiratory panels, point-of-care screening during surge events, and post-therapeutic monitoring for vulnerable populations. Concurrently, laboratory consolidation and the push for decentralized testing have reshaped how diagnostic services are delivered and consumed.

Clinical stakeholders increasingly prioritize speed, analytical performance, and operational simplicity, while health systems emphasize throughput, supply resilience, and cost-effectiveness. These intersecting priorities create a strategic imperative for diagnostics developers and distributors to align product design with real-world use cases across hospital laboratories, outpatient clinics, academic centers, and high-volume diagnostic laboratories. Moreover, regulatory clarity and reimbursement pathways remain decisive factors for adoption, necessitating proactive alignment between product development timelines and policy expectations.

In this context, the report synthesizes clinical drivers, technology readiness, supply chain considerations, and stakeholder incentives into a cohesive view that informs near-term commercial strategy and longer-term investment decisions. The intent is to provide an actionable framework that supports clinical leaders, R&D teams, and commercial strategists as they navigate the complex matrix of clinical need, performance trade-offs, and operational constraints.

How technological innovation, regulatory evolution, and operational resilience are collectively redefining where, how, and by whom influenza diagnostics are delivered

Recent years have seen transformative shifts in the influenza diagnostics landscape characterized by accelerated adoption of molecular testing modalities, greater demand for point-of-care solutions, and a rebalancing of centralized versus decentralized testing models. Innovations in isothermal amplification and integrated cartridge platforms have delivered robust alternatives to traditional PCR workflows, enabling rapid, near-patient diagnostics without compromising analytical sensitivity in many use cases. At the same time, improvements in assay multiplexing have expanded clinical utility by enabling simultaneous detection of multiple respiratory pathogens, which supports more informed clinical decision-making.

Parallel to these technological advances, operational shifts have emerged. Health systems have invested in flexible testing capacity to respond to seasonal surges and unexpected outbreaks, while laboratories have prioritized workflow automation and digital integration to improve throughput and data connectivity. Supply chain resiliency has become a top-tier imperative, prompting suppliers and purchasers to diversify sourcing strategies and to pursue regional manufacturing wherever feasible. Additionally, regulatory agencies globally have refined pathways for emergency use and accelerated approvals, creating windows of opportunity for innovative diagnostics that can demonstrate clinical value and operational fit.

Taken together, these shifts are not merely incremental; they change where testing occurs, who performs it, and how outcomes influence patient pathways. Strategic actors must therefore anticipate the confluence of technology maturation, regulatory evolution, and purchaser expectations to remain competitive and clinically relevant.

Assessing the multifaceted consequences of tariff-driven trade changes on supply chains, sourcing strategies, and procurement preferences within the diagnostics value chain

The introduction of tariffs and trade measures can have cascading effects across the diagnostics ecosystem, influencing component costs, supply chain design, and commercial strategy. Tariff-related cost pressures can raise the landed cost of imported reagents, disposables, and instrument components, thereby incentivizing manufacturers to reassess global sourcing strategies, relocate sensitive production steps, or negotiate longer-term supply contracts. In response, some firms accelerate efforts to diversify suppliers and to qualify alternative materials that preserve performance while mitigating exposure to trade disruptions.

In addition to direct cost implications, tariffs can influence competitive dynamics by altering the relative attractiveness of domestically manufactured versus imported products. For diagnostic companies with global footprints, tariff regimes can prompt restructuring of distribution footprints and pricing strategies to maintain market access while protecting margins. Health systems and laboratories, facing procurement constraints, may place higher value on supply resilience and vendor risk management, which influences procurement contracting and preferred supplier lists.

Regulatory and procurement environments also adapt. Policymakers may complement tariff actions with incentives for local manufacturing capacity, expedited regulatory reviews for domestically produced diagnostics, or strategic stockpiling initiatives. As a result, firms that can demonstrate local production capabilities, robust supply chains, and regulatory compliance gain a strategic advantage. Ultimately, navigating the tariff environment requires integrated cross-functional planning that aligns sourcing, manufacturing, regulatory, and commercial teams to sustain product availability and protect clinical continuity.

Detailed segmentation analysis illuminating how technology modalities and end-user channels dictate product specifications, adoption dynamics, and commercial approaches

Segmentation in influenza diagnostics spans technology modalities and end-user channels, each with distinct performance expectations and operational constraints. Within technology pathways, molecular diagnostics include conventional polymerase chain reaction approaches, isothermal amplification techniques, and real-time PCR platforms. Conventional PCR continues to serve reference laboratories where throughput and comprehensive validation are priorities, while isothermal amplification-comprising methods such as loop-mediated isothermal amplification and nucleic acid sequence-based amplification-has gained traction for its simplicity and suitability for decentralized testing. Real-time PCR, with configurations that support both multiplexing and singleplex formats, remains central to high-sensitivity applications and confirmatory workflows. Rapid diagnostics encompass cartridge-based platforms that integrate sample processing and detection for near-patient use, as well as lateral flow assays that provide quick, low-cost screening options. Serological diagnostics cover enzyme-linked immunosorbent assays, hemagglutination inhibition assays, and neutralization tests, which are critical for immune status assessment, vaccine evaluation, and epidemiologic surveillance.

From an end-user perspective, academic and research institutes seek flexible platforms that support method development and complex panels, while clinics require compact, easy-to-use solutions that deliver rapid actionable results. Diagnostic laboratories prioritize throughput, automation, and data interoperability, and hospitals demand scalable solutions that integrate with laboratory information systems and support inpatient care pathways. The interplay between technology choice and end-user requirements drives product specification, commercial packaging, and support models. For example, multiplex real-time PCR solutions are well aligned to reference laboratories and large hospitals where analytical depth and throughput are essential, whereas isothermal and cartridge-based systems better serve outpatient clinics and decentralized testing sites. Recognizing these alignments enables suppliers to tailor go-to-market strategies, prioritize regulatory submissions, and design service offerings that match operational realities across the clinical landscape.

How regional healthcare infrastructures, regulatory environments, and manufacturing footprints shape divergent adoption patterns and strategic priorities for diagnostics

Regional dynamics in influenza diagnostics reflect differences in healthcare infrastructure, regulatory regimes, and supply chain architectures across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, established laboratory networks and strong reimbursement frameworks drive demand for high-performance molecular assays and integrated laboratory solutions, while pockets of innovation have accelerated the adoption of point-of-care testing in community settings. Across Europe, the Middle East and Africa, regulatory harmonization efforts and variable health system capacities create a heterogeneous landscape in which centralized laboratories coexist with growing investments in decentralized testing to improve access, particularly in remote or resource-constrained areas. Procurement practices and public health surveillance priorities influence product selection and distribution models in this region.

In the Asia-Pacific, a combination of manufacturing capacity, government-led testing initiatives, and rapid uptake of novel platforms has positioned the region as both a major consumer and an important production hub for diagnostic components and assays. Local manufacturers have expanded capabilities across molecular and rapid diagnostics, supporting regional supply chain resilience and enabling tailored solutions for high-volume testing environments. These regional distinctions have implications for regulatory strategy, distribution partnerships, and localization of clinical validation efforts. Consequently, firms seeking regional scale must adapt regulatory submissions, local support models, and supply logistics to the distinct expectations and infrastructure realities of each geography.

Competitive dynamics driven by platform integration, strategic partnerships, and localized production that determine differentiation and long-term procurement relationships

The competitive field in influenza diagnostics is characterized by a mix of established diagnostics manufacturers, specialized molecular innovators, and an expanding set of cartridge and point-of-care platform developers. Large industry players continue to invest in platform integration, expanded assay menus, and global distribution networks, leveraging scale to support service models, quality assurance, and regulatory submissions. At the same time, agile technology companies drive innovation in isothermal methods, lab-on-a-chip integration, and rapid antigen detection enhancements, often partnering with clinical laboratories and research institutions to validate new applications.

Strategic partnerships between instrument providers and assay developers are increasingly important, enabling faster time-to-clinic for novel tests and creating ecosystems that link hardware, consumables, and digital services. In parallel, contract manufacturers and localized production sites have become key components of supply assurance strategies, particularly when trade measures or logistics disruptions constrain cross-border flows. Companies that demonstrate a combination of robust data package quality, responsive technical support, and flexible commercial models will be better positioned to win multi-year procurement agreements with health systems and large laboratory networks. Observing these dynamics, industry participants must balance product innovation with the operational rigor required by clinical customers.

Actionable priority initiatives for stakeholders to fortify supply resilience, align product design with clinical workflows, and accelerate adoption through strategic partnerships

Industry leaders can take proactive steps to strengthen resilience, accelerate adoption, and capture clinical value. First, aligning product development with prioritized clinical workflows-such as rapid rule-out in outpatient settings and multiplexed panels for inpatient management-ensures that performance features translate into actionable benefits for clinicians. Second, investing in supply chain diversification and regional manufacturing capacity reduces exposure to trade disruptions and supports faster delivery times during demand surges. Third, pursuing strategic alliances with laboratory networks, health systems, and academic centers accelerates real-world validation and builds credibility with large purchasers.

In addition, companies should prioritize regulatory strategy as a competitive asset, coordinating evidence generation to support approval pathways across target regions and anticipating changes in regulatory expectations. Commercially, flexible pricing and service models that reflect payer constraints and procurement cycles can unlock broader adoption, especially in decentralized settings. Finally, embedding digital connectivity and data analytics into product offerings enhances customer value by enabling quality control, remote troubleshooting, and integration with electronic health records. By executing on these imperatives, leaders can convert technical advantage into durable clinical and commercial outcomes.

An evidence-driven methodology combining primary stakeholder interviews, regulatory and technical documentation review, and cross-source triangulation to ensure rigorous and actionable findings

This research synthesizes primary interviews with clinical laboratory directors, procurement leads, and product development executives, combined with secondary analysis of regulatory guidance, peer-reviewed literature, and validated technical specifications from instrument and assay providers. The methodological approach emphasizes triangulation across data sources to ensure robustness: qualitative insights inform technology adoption narratives, while technical documentation underpins performance characterizations and interoperability considerations.

Field engagement included structured conversations to surface operational constraints, procurement criteria, and clinical decision drivers across hospitals, diagnostic laboratories, clinics, and academic centers. These insights were cross-referenced with regulatory filings and product technical manuals to ensure alignment between claimed capabilities and operational realities. Analytical frameworks prioritized technology readiness, integration complexity, and supply chain dependencies to produce strategic recommendations that are practical and evidence-based. Transparency in assumptions and clear documentation of data sources underpin the credibility of the findings and support reproducibility for stakeholders seeking to validate specific elements locally.

Concluding synthesis emphasizing the intersection of technological innovation, operational resilience, and strategic alignment as prerequisites for durable success in diagnostics

The evolving influenza diagnostics environment presents both complexity and opportunity. Technological advances in molecular and rapid testing, combined with shifts toward decentralized care and heightened supply chain scrutiny, are redefining value drivers for clinical customers. At the same time, geopolitical and trade developments underscore the need for flexible sourcing and regional manufacturing strategies. For industry participants, success will depend on the ability to integrate technical innovation with operational excellence, to navigate regulatory expectations across jurisdictions, and to demonstrate tangible clinical impact through real-world validations.

Strategic clarity-rooted in an understanding of end-user workflows, regional infrastructure, and competitive positioning-enables organizations to prioritize investments that deliver differentiated value. Those that couple reliable supply with customer-focused service models, regulatory preparedness, and targeted partnerships will be positioned to lead in both stable and surge-demand environments. Ultimately, informed action based on rigorous evidence and close engagement with clinical stakeholders will determine who captures the most durable opportunities in the influenza diagnostics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of rapid molecular point-of-care testing enabling near-patient influenza detection within minutes
  • 5.2. Development of multiplex respiratory panels integrating influenza A/B with other viral and bacterial targets
  • 5.3. Adoption of CRISPR-based diagnostic assays offering high sensitivity detection of influenza strains
  • 5.4. Integration of digital health platforms for remote monitoring and reporting of influenza test results
  • 5.5. Emergence of at-home self-collection kits for influenza testing with telehealth-guided interpretation
  • 5.6. Utilization of next-generation sequencing for comprehensive influenza virus surveillance and mutation tracking
  • 5.7. Growth of biomarker-based prognostic tests differentiating severe influenza cases for targeted therapy
  • 5.8. Increasing use of AI-driven analytics to predict influenza outbreaks and optimize diagnostic resource allocation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Diagnostics Market, by Technology

  • 8.1. Molecular Diagnostics
    • 8.1.1. Conventional PCR
    • 8.1.2. Isothermal Amplification
      • 8.1.2.1. Loop Mediated Isothermal Amplification
      • 8.1.2.2. Nucleic Acid Sequence Based Amplification
    • 8.1.3. Real Time PCR
      • 8.1.3.1. Multiplex PCR Kits
      • 8.1.3.2. Singleplex PCR Kits
  • 8.2. Rapid Diagnostics
    • 8.2.1. Cartridge Based Platforms
    • 8.2.2. Lateral Flow Assay
  • 8.3. Serological Diagnostics
    • 8.3.1. Elisa
    • 8.3.2. Hemagglutination Inhibition
    • 8.3.3. Neutralization Test

9. Influenza Diagnostics Market, by End User

  • 9.1. Academic & Research Institutes
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals

10. Influenza Diagnostics Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Influenza Diagnostics Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Influenza Diagnostics Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. F. Hoffmann-La Roche Ltd.
    • 13.3.2. Abbott Laboratories
    • 13.3.3. Quidel Corporation
    • 13.3.4. Becton, Dickinson and Company
    • 13.3.5. Thermo Fisher Scientific Inc.
    • 13.3.6. bioMerieux SA
    • 13.3.7. Hologic, Inc.
    • 13.3.8. Luminex Corporation
    • 13.3.9. Meridian Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 288. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 289. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 290. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 291. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 292. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 293. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 295. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. E